# Epitranscriptomic control of telomere maintenance

**Authors:** Ehsan Pashay Ahi, Zeinab Ghasemishahrestani

PMC · DOI: 10.1007/s11033-026-11699-w · 2026-03-19

## TL;DR

This review explores how RNA modifications influence telomere maintenance, linking chemical changes in RNA to telomere function and disease.

## Contribution

The paper integrates RNA modification systems into a framework for understanding telomere homeostasis and disease mechanisms.

## Key findings

- RNA modifications regulate telomerase activity and TERC processing.
- Telomeric RNA stability and function are influenced by RNA marks and readers.
- RNA modifications are linked to telomeropathies, aging, and cancer.

## Abstract

Telomere maintenance has been portrayed primarily as a problem of DNA–protein architecture and chromatin control, yet a complementary layer has been revealed at the level of RNA chemistry. In this Review, RNA modifications and their writer–reader–eraser and RNA-editing systems are integrated into a framework for chromosome-end homeostasis. Epitranscriptomic regulation of the telomerase ribonucleoprotein is examined, and assembly, activity, and recruitment are shown to be reshaped by chemical marks on TERC, specialized RNA capping, and processing pathways. Telomeric transcripts, particularly TERRA, are discussed as modified substrates whose stability, trafficking, and propensity for telomeric RNA: DNA hybrid formation can be tuned by RNA marks and their readers. Downstream consequences for replication stress, DNA damage signaling, and recombination-driven alternative lengthening of telomeres are summarized, together with emerging examples in which modification of telomere-factor mRNAs has been linked to rewiring of maintenance networks. Across these themes, links to telomeropathies, aging-associated inflammation, environmental stressors, and cancer are collated to connect mechanism to phenotype. Experimental bottlenecks and opportunities—site-resolved mapping, locus-targeted editing, and pharmacologic modulation of RNA-modifying enzymes—are outlined as routes toward causal models and therapeutic utilization.

## Linked entities

- **Diseases:** cancer (MONDO:0004992)

## Full-text entities

- **Genes:** TENT4B (terminal nucleotidyltransferase 4B) [NCBI Gene 64282] {aka PAPD5, TRF4-2, TUT3}, METTL14 (methyltransferase 14, N6-adenosine-methyltransferase non-catalytic subunit) [NCBI Gene 57721] {aka hMETTL14}, PML (PML nuclear body scaffold) [NCBI Gene 5371] {aka MYL, PP8675, RNF71, TRIM19}, RNPC3 (RNA binding region (RNP1, RRM) containing 3) [NCBI Gene 55599] {aka CPHD7, IGHD5, RBM40, RNP, SNRNP65}, YAP1 (Yes1 associated transcriptional regulator) [NCBI Gene 10413] {aka COB1, YAP, YAP-1, YAP2, YAP65, YKI}, SFPQ (splicing factor proline and glutamine rich) [NCBI Gene 6421] {aka POMP100, PPP1R140, PSF}, YTHDF2 (YTH N6-methyladenosine RNA binding protein F2) [NCBI Gene 51441] {aka CAHL, DF2, HGRG8, NY-REN-2}, ELAVL1 (ELAV like RNA binding protein 1) [NCBI Gene 1994] {aka ELAV1, HUR, Hua, MelG}, NONO (non-POU domain containing octamer binding) [NCBI Gene 4841] {aka MRXS34, NMT55, NRB54, P54, P54NRB, PPP1R114}, Mettl3 (methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit) [NCBI Gene 56335] {aka 2310024F18Rik, M6A, Spo8}, TLC1 (ncRNA) [NCBI Gene 9164870], YTHDC1 (YTH N6-methyladenosine RNA binding protein C1) [NCBI Gene 91746] {aka YT521, YT521-B}, RAD52 (RAD52 DNA repair protein) [NCBI Gene 5893], Primpol (primase and polymerase (DNA-directed)) [NCBI Gene 408022] {aka Ccdc111}, RTEL1 (regulator of telomere elongation helicase 1) [NCBI Gene 51750] {aka C20orf41, DKCA4, DKCB5, NHL, PFBMFT3, RTEL}, TYRO3 (TYRO3 protein tyrosine kinase) [NCBI Gene 7301] {aka BYK, Dtk, Etk-2, RSE, Rek, Sky}, TERC (telomerase RNA component) [NCBI Gene 7012] {aka DKCA1, PFBMFT2, SCARNA19, TER, TR, TRC3}, ATRX (ATRX chromatin remodeler) [NCBI Gene 546] {aka JMS, MRX52, RAD54, RAD54L, XH2, XNP}, Top3a (topoisomerase (DNA) III alpha) [NCBI Gene 21975], POT1 (protection of telomeres 1) [NCBI Gene 25913] {aka CMM10, CRMCC3, GLM9, HPOT1, PFBMFT8, TPDS3}, RPA1 (replication protein A1) [NCBI Gene 6117] {aka HSSB, MST075, PFBMFT6, REPA1, RF-A, RP-A}, TERF1 (telomeric repeat binding factor 1) [NCBI Gene 7013] {aka PIN2, TRBF1, TRF, TRF1, hTRF1-AS, t-TRF1}, RAD51 (RAD51 recombinase) [NCBI Gene 5888] {aka BRCC5, FANCR, HRAD51, HsRad51, HsT16930, MRMV2}, Dmrt2 (doublesex and mab-3 related transcription factor 2) [NCBI Gene 226049] {aka Terra}, ADAR (adenosine deaminase RNA specific) [NCBI Gene 103] {aka ADAR1, AGS6, DRADA, DSH, DSRAD, G1P1}, EXO1 (exonuclease 1) [NCBI Gene 9156] {aka HEX1, hExoI}, TERF2 (telomeric repeat binding factor 2) [NCBI Gene 7014] {aka TRBF2, TRF2}, TERT (telomerase reverse transcriptase) [NCBI Gene 7015] {aka CMM9, DKCA2, DKCB4, EST2, PFBMFT1, TCS1}, TRIR (telomerase RNA component interacting RNase) [NCBI Gene 79002] {aka C19orf43, TERCIR, fSAP18}, FTO (FTO alpha-ketoglutarate dependent dioxygenase) [NCBI Gene 79068] {aka ALKBH9, BMIQ14, GDFD, IFEX9}, BRCA1 (BRCA1 DNA repair associated) [NCBI Gene 672] {aka BRCAI, BRCC1, BROVCA1, FANCS, IRIS, PNCA4}, HNRNPA2B1 (heterogeneous nuclear ribonucleoprotein A2/B1) [NCBI Gene 3181] {aka HNRNPA2, HNRNPB1, HNRPA2, HNRPA2B1, HNRPB1, IBMPFD2}, ZBTB48 (zinc finger and BTB domain containing 48) [NCBI Gene 3104] {aka HKR3, TZAP, ZNF855, pp9964}, BRCA2 (BRCA2 DNA repair associated) [NCBI Gene 675] {aka BRCC2, BROVCA2, FACD, FAD, FAD1, FANCD}, PSPC1 (paraspeckle component 1) [NCBI Gene 55269] {aka PSP1}, TGS1 (trimethylguanosine synthase 1) [NCBI Gene 96764] {aka NCOA6IP, PIMT, PIPMT}, ALKBH5 (alkB homolog 5, RNA demethylase) [NCBI Gene 54890] {aka ABH5, OFOXD, OFOXD1}, TRAP [NCBI Gene 100187907], BLM (BLM RecQ like helicase) [NCBI Gene 641] {aka BS, MGRISCE1, RECQ2, RECQL2, RECQL3}, HMBOX1 (homeobox containing 1) [NCBI Gene 79618] {aka HNF1LA, HOT1, PBHNF, TAH1}, RBMS3 (RNA binding motif single stranded interacting protein 3) [NCBI Gene 27303], TAFAZZIN (tafazzin, phospholipid-lysophospholipid transacylase) [NCBI Gene 6901] {aka BTHS, CMD3A, EFE, EFE2, G4.5, LVNCX}, ARID1A (AT-rich interaction domain 1A) [NCBI Gene 8289] {aka B120, BAF250, BAF250a, BM029, C1orf4, CSS2}, TGS1 (RNA methyltransferase) [NCBI Gene 855946], Kdm1a (lysine (K)-specific demethylase 1A) [NCBI Gene 99982] {aka 1810043O07Rik, Aof2, D4Ertd478e, Kdm1, Lsd1, mKIAA0601}, RNASEH1 (ribonuclease H1) [NCBI Gene 246243] {aka H1RNA, PEOB2, RNH1}, RNPEP (arginyl aminopeptidase) [NCBI Gene 6051] {aka AP-B, APB}, METTL3 (methyltransferase 3, N6-adenosine-methyltransferase complex catalytic subunit) [NCBI Gene 56339] {aka IME4, M6A, MT-A70, Spo8, hMETTL3}, POU2F2 (POU class 2 homeobox 2) [NCBI Gene 5452] {aka OCT2, OTF2, Oct-2}
- **Diseases:** ALT (MESH:C536589), Alpha thalassemia (MESH:D017085), mental retardation syndrome X-linked (MESH:D038901), inflammation (MESH:D007249), inherited telomere biology disorders (MESH:D030342), telomere maintenance failure (MESH:D051437), Fat mass (MESH:C536030), neuroblastoma (MESH:D009447), TMM (MESH:D007319), cancer (MESH:D009369), Telomere biology (MESH:C536801), lung cancer (MESH:D008175)
- **Chemicals:** 7-methylguanosine (MESH:C016578), nucleotide (MESH:D009711), S-adenosylmethionine (MESH:D012436), Formalin (MESH:D005557), paraffin (MESH:D010232), DEHP (MESH:D004051), sinefungin (MESH:C006235), 5-methylcytosine (MESH:D044503), N6-methyladenosine (MESH:C010223), adenosine (MESH:D000241), 2,2,7-trimethylguanosine (MESH:C017778), Pseudouridine (MESH:D011560), N6,2'-O-dimethyladenosine (-)
- **Species:** Saccharomyces cerevisiae (baker's yeast, species) [taxon 4932], Homo sapiens (human, species) [taxon 9606], Caenorhabditis elegans (species) [taxon 6239]
- **Mutations:** A-to-I, T2T
- **Cell lines:** Cas13 — Homo sapiens (Human), Induced pluripotent stem cell (CVCL_A4EM)

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13002708/full.md

---
Source: https://tomesphere.com/paper/PMC13002708